{"id":{"repo_id":"uwo","oai_identifier":"oai:uwo.scholaris.ca:20.500.14721/29760"},"canonical_url":"https://search.dev.ndltd.org/etd/uwo/oai:uwo.scholaris.ca:20.500.14721/29760","repository":{"repo_id":"uwo","name":"Western University","base_url":"https://uwo.scholaris.ca/server/oai/request"},"display":{"title":"Is SABR cost-effective in oligometastatic cancer? An economic analysis of SABR-COMET randomized trial","abstract":"The phase II randomized study SABR-COMET demonstrated that in cancer patients with 1-5 oligometastatic lesions, stereotactic ablative radiotherapy (SABR) was associated with an improvement in both progression-free survival and overall survival compared to standard of care (SoC). SABR, however, is associated with higher costs and treatment-related toxicity. The objective of this study was to assess the cost-effectiveness of SABR versus SoC in patients with oligometastatic disease. A time-dependent Markov model with five health states was constructed from the Canadian health care system perspective. Utility values and transition probabilities were derived from the SABR-COMET trial. Costs were obtained from the published literature. A willingness-to-pay threshold of $100,000/quality adjusted life year (QALY) was used. SABR was cost-effective in the base case, at an incremental cost-effectiveness ratio of $37,157/ QALY gained over a lifetime horizon, as compared to the SoC. Therefore, administering SABR is cost-effective for patients with 1-5 oligometastatic lesions compared to SoC.","abstract_html":"The phase II randomized study SABR-COMET demonstrated that in cancer patients with 1-5 oligometastatic lesions, stereotactic ablative radiotherapy (SABR) was associated with an improvement in both progression-free survival and overall survival compared to standard of care (SoC). SABR, however, is associated with higher costs and treatment-related toxicity. The objective of this study was to assess the cost-effectiveness of SABR versus SoC in patients with oligometastatic disease. A time-dependent Markov model with five health states was constructed from the Canadian health care system perspective. Utility values and transition probabilities were derived from the SABR-COMET trial. Costs were obtained from the published literature. A willingness-to-pay threshold of $100,000/quality adjusted life year (QALY) was used. SABR was cost-effective in the base case, at an incremental cost-effectiveness ratio of $37,157/ QALY gained over a lifetime horizon, as compared to the SoC. Therefore, administering SABR is cost-effective for patients with 1-5 oligometastatic lesions compared to SoC.","abstract_has_math":true,"creators":["Chen, Yujie"],"institution":"The University of Western Ontario","degree_name":"M Sc","degree_level":null,"degree_discipline":"Epidemiology and Biostatistics","degree_department":null,"school":null,"contributors":[],"advisors":["Louie, Alexander","Zaric, Greg"],"committee_chairs":[],"committee_members":[],"year":2019,"date_issued":"2019-12-09","date_published":"2019-12-09","updated_at":"2026-07-27T21:56:13Z","subjects":["cost-effectiveness","stereotactic ablative radiotherapy (SABR)","oligometastases"],"languages":["en_ca"],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/20.500.14721/29760","outbound_label":"Handle","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Louie, Alexander","Zaric, Greg"]},{"key":"dc:creator","label":"Author","values":["Chen, Yujie"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2025-07-10T18:33:28Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2025-07-10T18:33:28Z"]},{"key":"dc:date.issued","label":"Date","values":["2019-12-09"]},{"key":"dc:publisher","label":"Institution","values":["The University of Western Ontario"]},{"key":"dc:type","label":"Dc Type","values":["thesis"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Epidemiology and Biostatistics"]},{"key":"thesis:degree_name","label":"Degree Name","values":["M Sc"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["cost-effectiveness","stereotactic ablative radiotherapy (SABR)","oligometastases"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en_ca"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/20.500.14721/29760"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["The thesis cover page in the PDF document includes references to Western University’s previous institutional repository platform, known as Scholarship@Western, and links to that platform (beginning with ir.lib.uwo.ca). In citing or referring to this thesis, use the DOI or handle from this page instead. Sample citation: Author name, \"Thesis title.\" (Year). Western University Open Repository. https://doi.org/10.71858/123456."]},{"key":"dc:description.abstract","label":"Abstract","values":["The phase II randomized study SABR-COMET demonstrated that in cancer patients with 1-5 oligometastatic lesions, stereotactic ablative radiotherapy (SABR) was associated with an improvement in both progression-free survival and overall survival compared to standard of care (SoC). SABR, however, is associated with higher costs and treatment-related toxicity. The objective of this study was to assess the cost-effectiveness of SABR versus SoC in patients with oligometastatic disease. A time-dependent Markov model with five health states was constructed from the Canadian health care system perspective. Utility values and transition probabilities were derived from the SABR-COMET trial. Costs were obtained from the published literature. A willingness-to-pay threshold of $100,000/quality adjusted life year (QALY) was used. SABR was cost-effective in the base case, at an incremental cost-effectiveness ratio of $37,157/ QALY gained over a lifetime horizon, as compared to the SoC. Therefore, administering SABR is cost-effective for patients with 1-5 oligometastatic lesions compared to SoC."]},{"key":"dc:title","label":"Title","values":["Is SABR cost-effective in oligometastatic cancer? An economic analysis of SABR-COMET randomized trial"]}]}],"canonical_facts":{"dc:contributor.advisor":["Louie, Alexander","Zaric, Greg"],"dc:creator":["Chen, Yujie"],"dc:date.accessioned":["2025-07-10T18:33:28Z"],"dc:date.available":["2025-07-10T18:33:28Z"],"dc:date.issued":["2019-12-09"],"dc:description":["The thesis cover page in the PDF document includes references to Western University’s previous institutional repository platform, known as Scholarship@Western, and links to that platform (beginning with ir.lib.uwo.ca). In citing or referring to this thesis, use the DOI or handle from this page instead. Sample citation: Author name, \"Thesis title.\" (Year). Western University Open Repository. https://doi.org/10.71858/123456."],"dc:description.abstract":["The phase II randomized study SABR-COMET demonstrated that in cancer patients with 1-5 oligometastatic lesions, stereotactic ablative radiotherapy (SABR) was associated with an improvement in both progression-free survival and overall survival compared to standard of care (SoC). SABR, however, is associated with higher costs and treatment-related toxicity. The objective of this study was to assess the cost-effectiveness of SABR versus SoC in patients with oligometastatic disease. A time-dependent Markov model with five health states was constructed from the Canadian health care system perspective. Utility values and transition probabilities were derived from the SABR-COMET trial. Costs were obtained from the published literature. A willingness-to-pay threshold of $100,000/quality adjusted life year (QALY) was used. SABR was cost-effective in the base case, at an incremental cost-effectiveness ratio of $37,157/ QALY gained over a lifetime horizon, as compared to the SoC. Therefore, administering SABR is cost-effective for patients with 1-5 oligometastatic lesions compared to SoC."],"dc:identifier.uri":["https://hdl.handle.net/20.500.14721/29760"],"dc:language.iso":["en_ca"],"dc:publisher":["The University of Western Ontario"],"dc:subject":["cost-effectiveness","stereotactic ablative radiotherapy (SABR)","oligometastases"],"dc:title":["Is SABR cost-effective in oligometastatic cancer? An economic analysis of SABR-COMET randomized trial"],"dc:type":["thesis"],"thesis:degree_discipline":["Epidemiology and Biostatistics"],"thesis:degree_name":["M Sc"]},"updated_at":"2026-07-27T21:56:13Z"}